Boston Scientific Corporation $BSX Shares Purchased by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Boston Scientific stake by 61.5% in the third quarter, purchasing 2.57 million additional shares and bringing its holdings to 6.74 million shares worth approximately $295.4 million.
• Institutional ownership remains high at 89.07%, with several major firms—including BlackRock, Primecap, Amundi and Arrowstreet Capital—also reporting significant positions or increased stakes.
• Boston Scientific beat quarterly earnings and revenue estimates, while analysts maintained a generally positive outlook: the stock has a consensus “Moderate Buy” rating and an average price target of $68.23.

Assenagon Asset Management S.A. increased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 61.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,740,683 shares of the medical equipment provider's stock after purchasing an additional 2,567,124 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.47% of Boston Scientific worth $295,377,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at $5,534,781,000. Primecap Management Co. CA purchased a new position in Boston Scientific in the second quarter valued at about $2,156,233,000. Janus Henderson Group PLC grew its stake in Boston Scientific by 5.2% in the fourth quarter. Janus Henderson Group PLC now owns 12,589,385 shares of the medical equipment provider's stock valued at $1,200,404,000 after purchasing an additional 617,515 shares in the last quarter. Amundi grew its stake in Boston Scientific by 13.8% in the first quarter. Amundi now owns 14,122,913 shares of the medical equipment provider's stock valued at $886,213,000 after purchasing an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in Boston Scientific by 25.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider's stock worth $871,702,000 after purchasing an additional 2,856,040 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 2.7%

Shares of BSX stock opened at $44.17 on Friday. The company has a market capitalization of $64.02 billion, a P/E ratio of 13.40, a P/E/G ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a 12-month low of $41.38 and a 12-month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $46.16 and a 200 day moving average price of $49.80.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company's revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 2nd. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. TD Cowen reaffirmed a "buy" rating on shares of Boston Scientific in a research note on Thursday, September 17th. Needham & Company LLC decreased their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a report on Wednesday, July 8th. Finally, UBS Group decreased their price target on shares of Boston Scientific from $74.00 to $67.00 and set a "buy" rating for the company in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $68.23.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael Mahoney bought 186,240 shares of the company's stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David Habiger purchased 2,100 shares of the firm's stock in a transaction dated Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company's stock, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.